These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25776511)

  • 61. Octreotide-modification enhances the delivery and targeting of doxorubicin-loaded liposomes to somatostatin receptors expressing tumor in vitro and in vivo.
    Sun M; Wang Y; Shen J; Xiao Y; Su Z; Ping Q
    Nanotechnology; 2010 Nov; 21(47):475101. PubMed ID: 21030757
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Tamoxifen guided liposomes for targeting encapsulated anticancer agent to estrogen receptor positive breast cancer cells: in vitro and in vivo evaluation.
    Jain AS; Goel PN; Shah SM; Dhawan VV; Nikam Y; Gude RP; Nagarsenker MS
    Biomed Pharmacother; 2014 May; 68(4):429-38. PubMed ID: 24721327
    [TBL] [Abstract][Full Text] [Related]  

  • 63. GE11-antigen-loaded hepatitis B virus core antigen virus-like particles efficiently bind to TNBC tumor.
    Zhang L; Tang L; Jiang Y; Wang C; Huang L; Ding T; Zhang T; Li H; Xie L
    Front Oncol; 2023; 13():1110751. PubMed ID: 37020877
    [TBL] [Abstract][Full Text] [Related]  

  • 64. GE11 peptide-decorated acidity-responsive micelles for improved drug delivery and enhanced combination therapy of metastatic breast cancer.
    Guo Z; Sui J; Li Y; Wei Q; Wei C; Xiu L; Zhu R; Sun Y; Hu J; Li JL
    J Mater Chem B; 2022 Nov; 10(44):9266-9279. PubMed ID: 36342458
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Large-scale manufacturing of GMP-compliant anti-EGFR targeted nanocarriers: production of doxorubicin-loaded anti-EGFR-immunoliposomes for a first-in-man clinical trial.
    Wicki A; Ritschard R; Loesch U; Deuster S; Rochlitz C; Mamot C
    Int J Pharm; 2015 Apr; 484(1-2):8-15. PubMed ID: 25701632
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Design of a doxorubicin-peptidomimetic conjugate that targets HER2-positive cancer cells.
    Pallerla S; Gauthier T; Sable R; Jois SD
    Eur J Med Chem; 2017 Jan; 125():914-924. PubMed ID: 27769032
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Synthesis and characterization of cisplatin-loaded, EGFR-targeted biopolymer and in vitro evaluation for targeted delivery.
    Geng X; Ye H; Feng Z; Lao X; Zhang L; Huang J; Wu ZR
    J Biomed Mater Res A; 2012 Oct; 100(10):2839-48. PubMed ID: 22678850
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Enhanced EGFR Targeting Activity of Plasmonic Nanostructures with Engineered GE11 Peptide.
    Biscaglia F; Rajendran S; Conflitti P; Benna C; Sommaggio R; Litti L; Mocellin S; Bocchinfuso G; Rosato A; Palleschi A; Nitti D; Gobbo M; Meneghetti M
    Adv Healthc Mater; 2017 Dec; 6(23):. PubMed ID: 28945012
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Inhibitory Effect of Oxaliplatin-loaded Engineered Milk Extracellular Vesicles on Tumor Progression.
    Go G; Park HJ; Lee JH; Yun CW; Lee SH
    Anticancer Res; 2022 Feb; 42(2):857-866. PubMed ID: 35093883
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Review on the binding of anticancer drug doxorubicin with DNA and tRNA: Structural models and antitumor activity.
    Agudelo D; Bourassa P; Bérubé G; Tajmir-Riahi HA
    J Photochem Photobiol B; 2016 May; 158():274-9. PubMed ID: 26971631
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Selective Delivery of Doxorubicin to EGFR
    Liu T; Song P; Märcher A; Kjems J; Yang C; Gothelf KV
    Chembiochem; 2019 Apr; 20(8):1014-1018. PubMed ID: 30589193
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Challenges for the application of EGFR-targeting peptide GE11 in tumor diagnosis and treatment.
    Hailing T; Yonghong P; Yufeng Z; Haitao T
    J Control Release; 2022 Sep; 349():592-605. PubMed ID: 35872181
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Albumin Binding Domain Fusing R/K-X-X-R/K Sequence for Enhancing Tumor Delivery of Doxorubicin.
    Liu L; Zhang C; Li Z; Wang C; Bi J; Yin S; Wang Q; Yu R; Liu Y; Su Z
    Mol Pharm; 2017 Nov; 14(11):3739-3749. PubMed ID: 28950700
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Overcoming drug resistance by cell-penetrating peptide-mediated delivery of a doxorubicin dimer with high DNA-binding affinity.
    Lelle M; Freidel C; Kaloyanova S; Tabujew I; Schramm A; Musheev M; Niehrs C; Müllen K; Peneva K
    Eur J Med Chem; 2017 Apr; 130():336-345. PubMed ID: 28273560
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Taming the Wildness of "Trojan-Horse" Peptides by Charge-Guided Masking and Protease-Triggered Demasking for the Controlled Delivery of Antitumor Agents.
    Shi NQ; Qi XR
    ACS Appl Mater Interfaces; 2017 Mar; 9(12):10519-10529. PubMed ID: 28290666
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Toward the Development of GE11-Based Radioligands for Imaging of Epidermal Growth Factor Receptor-Positive Tumors.
    Judmann B; Braun D; Schirrmacher R; Wängler B; Fricker G; Wängler C
    ACS Omega; 2022 Aug; 7(31):27690-27702. PubMed ID: 35967067
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Conjugate of PAMAM Dendrimer, Doxorubicin and Monoclonal Antibody-Trastuzumab: The New Approach of a Well-Known Strategy.
    Marcinkowska M; Sobierajska E; Stanczyk M; Janaszewska A; Chworos A; Klajnert-Maculewicz B
    Polymers (Basel); 2018 Feb; 10(2):. PubMed ID: 30966223
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Graphene quantum dots-based targeted nanoprobes detecting drug delivery, imaging, and enhanced chemotherapy of nasopharyngeal carcinoma.
    Yu C; Long Z; Qiu Q; Liu F; Xu Y; Zhang T; Guo R; Zhong W; Huang S; Chen S
    Bioeng Transl Med; 2022 May; 7(2):e10270. PubMed ID: 35600653
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Anti-EGFR Targeted Multifunctional I-131 Radio-Nanotherapeutic for Treating Osteosarcoma: In Vitro 3D Tumor Spheroid Model.
    Marshall SK; Saelim B; Taweesap M; Pachana V; Panrak Y; Makchuchit N; Jaroenpakdee P
    Nanomaterials (Basel); 2022 Oct; 12(19):. PubMed ID: 36234645
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Engineered extracellular vesicles with polypeptide for targeted delivery of doxorubicin against EGFR‑positive tumors.
    Yang Y; Wang F; Li Y; Chen R; Wang X; Chen J; Lin X; Zhang H; Huang Y; Wang R
    Oncol Rep; 2024 Nov; 52(5):. PubMed ID: 39329273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.